1	Impact of Vitamin D supplementation on cognition in adults with mild to moderate vitamin D
2	deficiency: Outcomes from the VitaMIND randomised controlled trial.
3	
4	Short Title: RCT of vitamin D in adults at risk of dementia
5	
6	Anne Corbett PhD <sup>1*</sup> , Rod Taylor PhD <sup>2</sup> , David Llewellyn PhD <sup>1</sup> , Janice M. Ranson PhD <sup>1</sup> , Adam
7	Hampshire PhD <sup>3</sup> , Ellie Pickering MSc <sup>1</sup> , Abbie Palmer BSc <sup>1</sup> , Dag Aarsland MD <sup>3</sup> , Dorina Cader PhD <sup>4</sup> ,
8	Diana Frost <sup>1</sup> , Clive Ballard MD <sup>1</sup>
9	
10	
11	<sup>1</sup> Department of Health & Community Sciences, University of Exeter Medical School, University of
12	Exeter, Exeter EX1 2LU, UK
13	<sup>2</sup> MRC/CSO Social and Public Health Sciences Unit & Robertson Centre for Biostatistics, School of
14	Health and Well Being, University of Glasgow, Glasgow, G12 8QQ, Scotland
15	<sup>3</sup> Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SW7 2AZ, UK
16	<sup>4</sup> Brighton & Sussex Medical School, University of Sussex, Brighton BN1 9RY
17	
18	* Corresponding Author
19	Anne Corbett
20	Address: University of Exeter Medical School, St Luke's Campus, University of Exeter, Exeter, EX1
21	2LU, UK
22	Email: <u>a.m.j.corbett@exeter.ac.uk</u> Tel: 01392724464
23	ORCID ID: 0000-0003-2015-0316
24	Word Count: 5619
25	

#### 26 Abstract

### 27 Background

- 28 Preserved cognitive health with ageing is a public health imperative. Vitamin D deficiency is
- associated with poor cognition, but it is unclear whether supplementation would provide benefit,
- 30 particularly in individuals with mild/moderate deficiencies which do not have other clinical risks.
- 31 The objective of this study was to establish the impact of daily vitamin D supplementation on
- 32 cognition in older adults with mild to moderate vitamin D deficiency.

## 33 Methods and Findings

- 34 Two-arm parallel 24-month randomised controlled trial, with Vitamin D supplementation compared
- 35 with a placebo. This was a remote trial, completed from home involving 620 adults 50 years or older
- 36 with mild to moderate vitamin D deficiency and early cognitive impairment. The primary outcome
- 37 was executive function measured through Trail making B and other secondary measures of
- 38 cognition, function and wellbeing.
- 39 Vitamin D supplementation conferred no significant benefit to executive function compared to
- 40 placebo at follow-up on the primary outcome (between-group difference: 5770, 95% CI: -2189 to
- 41 13730) or cognition, function, or wellbeing. Secondary analyses in defined subgroups and a per-
- 42 protocol analysis also showed no significant impact on any outcome measures.

#### 43 Conclusions

- 44 Vitamin D supplementation produced no measurable improvement in cognitive outcomes in older
- 45 adults with mild to moderate vitamin D deficiency. The remote trial methodology provides an
- 46 innovative approach to large-scale trials.
- 47 Trial Registration: ISRCTN79265514 https://www.isrctn.com/ISRCTN79265514
- 48 Word count: 218
- 49

## 50 Introduction

51	Dementia is a devastating condition that affects over 850,000 people in the UK and carries enormous
52	emotional, societal and financial burdens, with an estimated cost of £26.3 billion each year to the UK
53	health service(1). Worldwide, this figure reaches US\$818billion. While new disease-modifying
54	treatments are in the pipeline, there is a continuing imperative to deliver approaches to reduce the
55	risk of cognitive decline and dementia, particularly in high-risk groups. The largest at-risk group for
56	dementia are individuals with Mild Cognitive Impairment (MCI), which affects 10-20% of older
57	adults, of whom up to 10% develop dementia each year(2). A larger and less well-defined group of
58	individuals experience Age-Associated Cognitive Decline (AACD), a risk state for MCI, which has been
59	clinically defined by recent diagnostic criteria(3). The opportunity to apply precision medicine
60	approaches to risk reduction in these groups would enable tailored treatment and preventative
61	interventions to be targeted in the most impactful way to achieve better public health. The potential
62	impact of such a strategy to preserve cognition in older age and delay the onset of dementia
63	symptoms, even by a few months, could have a significant impact at a population level and improve
64	the health and wellbeing of older adults.
65	There is good evidence to support several approaches for reducing the risk of dementia. One
66	promising avenue is through supplementation of dietary deficiencies, particularly with Vitamin D.
67	Vitamin D deficiency is prevalent in the UK, particularly in the winter months. The Scientific Advisory
68	Committee on Nutrition reports that 23% of adults fulfil criteria for severe vitamin D deficiency,
69	categorised as clinically at risk of reduced bone mineralisation, causing bone pain, muscle pain and
70	fatigue, and potential impacts on respiratory and cardiovascular conditions (< 25nmol/L of 25-
71	hydroxy-vitamin D (25(OH)D) in the blood), while 40.4% fulfil criteria for inadequate levels
72	(<50nmol/l)(4-6). These figures highlight the prevalence of deficiency across the UK population.
73	Seasonality is a significant factor in levels, with severe deficiency prevalence rising from 23% to 29%
74	in adults over 65 from summer to winter months. Dietary supplementation, therefore, offers a
75	means of significantly increasing vitamin D levels above the current UK baseline.

76

77	A rapidly growing body of evidence indicates that Vitamin D may play a role in brain health and
78	cognition. Vitamin D receptors (VDR), one of the nuclear receptor family of transcription factors, are
79	found extensively throughout the brain, and they are associated with neuroprotection and anti-
80	inflammatory effects(7). For example, vitamin D reduces the hallmarks of Alzheimer's disease,
81	including amyloid beta in in vitro models(8, 9). Vitamin D was first identified as a potential
82	intervention for dementia prevention in 2009 by a study that linked low vitamin D levels in 1,766
83	older adults to cognitive impairment(10). Subsequently, a large prospective study established that
84	severe vitamin D deficiency (<25 nmol/L) was associated with a risk of substantial cognitive decline
85	over six years by around 60%, and a more recent study showed that vitamin D exposure was
86	associated with a significant reduction in dementia risk, particularly in individuals at greater risk of
87	dementia(11). People with severe vitamin D deficiency are 120% more likely to develop dementia
88	over six-years(12). These landmark studies have been replicated by other groups and confirmed in a
89	series of systematic reviews and meta-analyses(13, 14). This evidence base, in addition to clinical
90	links to conditions such as osteoporosis and osteoarthritis, clearly shows the importance of treating
91	severe vitamin D deficiency to improve cognitive health. The strength of this evidence would
92	preclude a randomised trial in these patients since the benefit to health is so clear. However, the
93	case is less clear-cut with regard to mild and moderate deficiency, where a trial is warranted. A
94	meta-analysis of 37 studies explored cognitive performance in people above and below the mild
95	deficiency threshold of 50nmol/l and reported significantly worse cognition in individuals with mild
96	vitamin D deficiency. A further observational and Mendelian randomisation study also showed non-
97	linear associations of dementia risk in individuals up to 50nmol/l(15, 16) Therefore, the key
98	emerging question is whether treating mild to moderate vitamin D deficiency confers benefits
99	regarding cognitive outcomes.
100	People with severe vitamin D deficiency are usually identified and treated through established

101 clinical care pathways, ensuring that their resulting dementia risk and other health issues are likely

102	to be mitigated through effective supplementation. However, mild to moderate deficiencies of 25-
103	50nmol/l are less likely to be detected despite being prevalent in the community. There is a need to
104	establish whether supplementation of these groups could improve cognitive outcomes and whether
105	this should be incorporated into risk reduction strategies for wider public health initiatives. This
106	study conducts a definitive trial to determine whether Vitamin D supplementation is an effective
107	means of maintaining cognitive function in people with mild to moderate vitamin D deficiency. Trials
108	of this nature, which are investigating low-risk interventions in a large cohort of individuals in the
109	community, offer the opportunity to employ innovative remote trial methodologies, using a
110	combination of online assessment, digital tools for engagement, and remote dispensing approaches
111	to deliver large-scale trials without the need for in-person clinic visits and assessments. The
112	PROTECT-UK platform offers the infrastructure to deliver remote, virtual trials(17). This study
113	represents the first large-scale proof of concept for this model of trial delivery.
114	
115	Methods
116	Study Design
117	This VitaMIND study was a parallel, double-blind, 24-month remote randomised controlled trial to
118	establish the impact of vitamin D supplementation on cognition, function and wellbeing in adults
119	over 50 with mild to moderate vitamin D deficiency and age-associated cognitive decline. The study
120	was approved by the Wales Research Ethics Committee 3 under the UK Health Research Authority
121	(Ref 19/WA/0007). The protocol is registered on the ISRCTN database (Ref: ISRCTN79265514). The
122	study is reported in accordance with CONSORT guidelines (ref). Patients, clinicians, and the research
123	team were all blinded to group allocation.
174	

124

125 Participants

126 Adults over the age of 50 in the UK were invited to take part through the UK online ageing cohort,

127 PROTECT(17, 18). All participants were already registered on the PROTECT cohort and were invited

128	to the trial by email correspondence as part of the consent for contact in place in the PROTECT
129	cohort. Eligible participants were over the age of 50, without a diagnosis of dementia, had access to
130	a computer and the internet, fulfilled criteria for high risk of vitamin D deficiency of 50nmol/l
131	25(OH)D or below based on a self-reported screening questionnaire (Table1) and fulfilled criteria for
132	AACD (performing one standard deviation below norm on at least one cognitive test in the PROTECT-
133	UK Cognitive Test System, described elsewhere)(19). The PROTECT-UK cohort was pre-screened for
134	age and AACD criteria. Interested individuals registered and provided consent for the study through
135	an ethically approved digital consent process embedded on the PROTECT website. Participants then
136	accessed the trial by navigating to the VitaMIND trial area on their online dashboard. Automated
137	emails were scheduled to remind participants to take their study tablets and complete their
138	cognitive assessments.
139	
140	Screening Questionnaire for Vitamin D deficiency
141	In order to identify participants with Vitamin D deficiency (<50 nmol/L), predictive algorithms were
142	trained using data from 3,519 community-dwelling participants aged 50 and over from the English
143	Longitudinal Study of Aging (ELSA)(20). Potential predictors were based on those identified in
144	previous risk prediction models for vitamin D deficiency, as well as those with an established
145	association with vitamin D levels. In the absence of a suitable external test dataset, split-sample
146	development and validation were conducted (80% used for development, 20% for validation).
147	Missing data was dealt with using multivariate imputation by chained equations. Predictors were
148	selected using multivariable fractional polynomial bootstrapped regression with 1000 bootstrap
149	replications. Ten predictors were included in the final algorithm: Body mass index, treatment for
150	osteoporosis, month of assessment, smoking status, exercise, marital status, age, alcohol
151	consumption, ethnicity and self-rated poor health. See Table 1 for full details of the questionnaire
152	and response options. Participants with a 30% or higher predicted probability of mild Vitamin D
153	deficiency (<50 nmol/L) were eligible for the study.

# 154 Table 1: Screening questionnaire and algorithm for vitamin D deficiency

Description	Wording	Response options	Notes		
ВМІ	How much do you weigh? How tall are you?	Kg or stones and pounds Meters or feet and inches	To calculate BMI Either: Weight (kg) / height (m) <sup>2</sup> Or: Weight (lb) / height (in)*703 (in which case, weight first needs to be converted to lbs and height converted to inches.		
Treatment for osteoporosis	Do you take calcium pills or Vitamin D for osteoporosis, sometimes called thin or brittle bones?	Yes / No	'No' is the reference category		
Month of	N/A	N/A			
Physical activity	<ul> <li>A. Do you take part in sports or activities that are vigorous?</li> <li>B. Do you take part in sports or activities that are moderately energetic?</li> <li>C. Do you take part in sports or activities that are mildly energetic?</li> </ul>	A1 More than once a week A2 Once a week A3 1-3 times a month A4 Hardly ever or never B1 More than once a week B2 Once a week B3 1-3 times a month B4 Hardly ever or never C1 More than once a week C2 Once a week C3 1-3 times a month C4 Hardly ever or never	Physical activity has four categories depending on combination of responses to these three questions: '0' is the reference category A participant is assigned to the lowest number category for which they are eligible. Category response requirements are below: 0 = High (A1) 1 = Moderate (B1 or B2) or (A2 or A3) 2 = Low (C1 or C2) or (B2 or B3 or B4) + (A4) 3 = Sedentary (C3 or C4) + (B4) + (A4)		
Current smoking status	Do you currently smoke cigarettes, cigars or a pipe?	Yes / No	'No' is the reference category		
Age	What is your date of birth?	Date / Month / Year			
Couple status	Are you currently married or living with a partner?	Yes / No	'Yes' is the reference category		
Ethnicity	To which of these groups	White / Mixed /	0/1 binary variable		

	do you consider that you belong?	Black / Black British / Asian / Asian British /Other	'White' versus all other categories. 'White' is the reference category.			
Weekly alcohol consumption	During the last seven days, how many measures of spirits did you have?	Continuous	The responses to these three questions need to be totalled to produce a single weekly			
	During the last seven days, how many glasses of wine did you have?	Continuous	number of drinks.			
	During the last seven days, how many pints of beer did you have?	Continuous				
Self-rated poor health	Would you say your health is	Excellent / Very good / Good / Fair / Poor	0/1 binary variable 'Poor' versus all other categories. 'Other' is the reference category.			
A la suith us to usualist Miteuriu. Dala Galence (UEOusual (II)						

Algorithm to predict Vitamin D deficiency (<50nmol/l) gen pred vitd50= -2.987615 + (bmi\*.0642204) + (osteomed\*-1.178731) + (((month/10)^3-

.4303164208)\*-1.336699) + (((month/10)^3\*ln(month/10)+.1209525476)\* 7.583981) + (smoker\*.7837381) + (exercise\_1\*.4699397) + (exercise\_2\*.7609146) + (exercise\_3\*.7766721) + (((age/10)^2-44.36322732)\*-.1511723) + (((age/10)^3-295.4844962)\*.0147316) + (couple\*.4051173) + (ethnic\*1.224978) + ((((drink+1)/10)^-.5-1.226242542)\*.1254607) + (selfhealthpoor\*.1064709)

Gen prob\_vitd50 = (exp (pred\_vitd50) / (1+exp (pred\_vitd50)))\*100

155

- 156 Treatment Interventions
- 157 Participants were randomised to receive either 4000IU Vitamin D3, supplied in two-piece HPMC
- 158 capsules, or an identical placebo capsule without the active Vitamin D3 supplement. This dose is the
- 159 highest publicly available vitamin D3 supplement and was chosen for relevance to existing available
- 160 treatments and due to known safety data. Capsules were provided in blister packs of 28, stamped
- 161 with the days of the week to aid compliance. Participants were instructed to take one tablet daily for
- 162 the 24-month duration of the study.

163

164 *Outcome Measures* 

165 Outcome measures were completed at baseline, six, 12 and 24 months. All outcome measures were

166 completed online through the PROTECT cohort platform.

1	6	7
_		

169

### 168 Primary Outcome Measure

170	computerised version of the well-validated Trail making B task in which a participant connects an
171	alternating sequence of alphanumeric characters(21). Total time and accuracy are captured and
172	combined to provide a total score.
173	
174	Secondary Outcome Measures
175	Secondary cognitive outcomes were measured using a wider computerised cognitive test system
176	consisting of five cognitive tests described in full in previous papers (22) (18, 23). The test system
177	included measures of spatial working memory (Paired Associate Learning, Self-Ordered Search),
178	numerical working memory (Digit Span) and executive function (Verbal Reasoning, Switching

The primary outcome measure was executive function and task-switching as measured by a

179 Stroop). Additional secondary outcome measures were also collected to assess function

180 (Instrumental Activities of Daily Living), behaviour (Mild Behaviour Impairment Scale) and wellbeing

181 (EQ5D)(24-26).

182

183 Sample Size

The sample size calculation was based on a published study of online cognitive training in adults over 50, which showed significant change in executive function in adults with AACD (27). Based on an effect size of 0.3, which is clinically meaningful and has been achieved through similar trials in this field, 165 participants would be required for each group to provide 80% power at a two-sided 0.05 significance level, assuming a conservative drop-out rate of 40%. Therefore, a total of at least 462 participants (231 per group) were required for this trial.

190

191 Randomisation and masking

192	Randomisation of participants was achieved through a purpose-built algorithm embedded in REDCap
193	Cloud. Randomisation occurred after a participant had completed their baseline assessments. The
194	algorithm allocated participants randomly, stratifying for age (age brackets of five years), gender and
195	Vitamin D deficiency severity (mild-moderate (< 50 nmol/L) or severe (< 25 nmol/L) Vitamin D level).
196	
197	The treatment allocation of participants was recorded electronically in REDCap Cloud, hosted by the
198	University of Exeter's Clinical Trials Unit. This ensured that both participants and the research team
199	were blind to allocation, thus removing any bias. Study staff with direct participant contact were not
200	involved in any data analysis, thus avoiding any unconscious bias as a result of their contact.
201	
202	Safety Monitoring
203	All AEs and SAEs occurring from the time of the start of trial treatment until the end of the trial
204	were reported by participants using an online form. Participants were prompted to enter any
205	details of events at each quarterly login event and encouraged to report any event proactively using
206	the online form or by contacting the study team by telephone and email. All AEs were logged and
207	reported to the study team for review within 24 hours.
208	
209	Compliance
210	Participants completed a regular tablet count record on the study website to track compliance
211	across the full study and to support the per-protocol analysis. Ten per cent of the cohort was also
212	randomly selected to complete finger-prick blood tests at baseline and 24 months to quantify
213	vitamin D blood levels. Participants received the vitamin D blood spot test kit in the post, completed
214	the tests at home according to the kit instructions, and returned them to the Sandwell and West
215	Birmingham NHS Foundation Trust laboratory for analysis.
216	

217 Data Analysis

218 Analysis was performed according to a prespecified statistical analysis plan. The primary analyses 219 compared primary and secondary outcomes between intervention and control groups at 24 months 220 using linear regression models with adjustment for baseline outcome score and stratification 221 variables. Primary analyses were based on an intention-to-treat (ITT) approach. 222 223 A number of secondary analyses were undertaken. A repeated measures analysis using a mixed 224 effects linear regression model with a random effect on participants) for primary and secondary 225 continuous outcomes, to compare intervention and control groups including data from participants 226 with observed data for at least one of the three follow-up timepoints. A fixed effect interaction 227 between the time point and trial arm was used to evaluate differential treatment effects across time 228 points. Adjustments for baseline covariates were made for the primary analysis regression models. 229 Multiple imputation using chained equations was used to impute missing primary and secondary 230 continuous outcome data. Imputation models were informed by the treatment arm, baseline scores, 231 and stratification covariates to be included in the primary analysis model. Primary analysis models 232 for primary and secondary outcomes were rerun using imputed data sets. To assess the potential 233 effect of tablet adherence, an additional analysis was undertaken with the primary ITT 234 analysis adjusted for the difference in baseline and 24-month follow-up tablet count. Blood 235 test data for compliance was analysed using a t-test. 236 Role of Funding Source 237 The funder had no input into the study's design, interpretation of results, writing of the manuscript, 238 or decision to publish. 239

240 Results

241 Cohort Characteristics

242 620 participants consented to the study between 1<sup>st</sup> September 2020 and 26<sup>th</sup> March 2021, of whom

243 75% were female, with an average age of 60 (SD 6.58) and an average educational attainment

- corresponding to completion of secondary education with an additional vocational qualification. 310
- 245 participants were randomised to the Vitamin D intervention group, and 310 were randomised to the
- control group. There were no significant differences between the characteristics of the two groups.
- 247 In the sub-group of participants who completed a blood sample at baseline, the median vitamin D
- level was 42 nmol/l with no significant difference between groups (p=0.44). The baseline
- characteristics of the study participants are described in Table 2, and the flow of participant
- selection through the study is presented in Figure 1. The trial ended after the last follow-up
- assessment of the last participant was completed.

## 252 Table 2: Cohort characteristics for the VitaMIND trial

Characteristic		Full cohort n = 620	VitaMIND group n = 310	Control group n = 310	
Age	Range Mean (SD)	50 – 80 60.7 (6.58)	50 – 80 60.3 (6.27)	50 – 80 60.8 (6.73)	
Sov	Male n (%)	154 (25%)	75 (25%)	79 (25%)	
Sex	Female n (%)	466 (75%)	235 (75%)	231 (75%)	
Educational	Mean	3.17	3.19	3.14	
attainment	(SD)	(1.38)	(1.35)	(1.41)	
	White n (%)	608 (98)	301 (97)	303 (98)	
Ethnicity	Mixed n (%)	4 (<1)	3 (<1)	1(<1)	
Etimicity	Asian n (%)	7 (<1)	3 (<1)	4 (<1)	
	Black n (%)	1 (<1)	1 (<0.5)	0 (0)	

253

## 254 Fig 1. CONSORT chart showing the flow of participants through the VitaMIND trial

255

256 Impact of Vitamin D on cognitive outcomes

257 Analysis showed no significant benefits to cognition in the Vitamin D intervention group compared

- to placebo at 24 months. In the primary outcome of executive function measured by the Trail
- 259 making task, the ReaCT intervention conferred no significant benefit compared to the control task
- 260 (Cohen's D Effect Size (ES) 0.11; P=0.16) (Table 3). In the secondary outcome measures, the
- 261 treatment group also showed no significant benefit compared to the control group in numerical
- working memory (ES 0.08; P=0.38)), spatial working memory (Paired Associate Learning P=0.84; Self-

263 Ordered Search P=0.64) or executive function (Switching Stroop P=0.86; Verbal Reasoning P=0.92)

264 (Table 3).

265

## Impact of the START intervention on function, wellbeing and behaviour

In the non-cognitive secondary outcome measures, the treatment group also showed no significant

benefit compared to the control group in function (P=0.86), behaviour (P=0.65) or wellbeing (P=0.92)

(Table 3).

## Table 3: Impact of Vitamin D supplementation on executive function (primary outcome), cognition

(Secondary outcomes), function, behaviour and wellbeing at 24 months

	Vitamin D Group		Control Group		Between group		
	Baseline	2-years	Baseline	2-years	difference*		Effort
	N mean (SD)	N mean (SD)	N mean SD	N mean SD	Mean (95% Cl),	P- value	size
Primary outco	me						
Trail making B	310 61869 (27299)	174 61388 (22976)	310 61421 (31949)	163 55954 (49506)	5770 (- 2189 to 13730)	0.16	0.116552
Secondary cog	nitive outcoi	nes		-		-	
Baddeley Grammatical Reasoning	310 36.0 (11.7)	169 37.8 (11.4)	310 36.7 (11.8)	150 37.7 (10.8)	0.1 (-1.4 to 1.5)	0.92	0.009259
Switching Stroop	310 40.2 (17.6)	174 44.5 (17.2)	310 41.5 (17.0)	163 43.2 (18.6)	0.7 (-2.2 to 3.7)	0.63	0.037634
Paired Associate Learning	310 3.98 (1.02)	170 4.11 (0.92)	310 4.04 (1.18)	155 4.17 (0.95)	-0.02 (-0.21 to 0.17)	0.84	0.021053
Digit Span	310 7.32 (1.64)	166 7.51 (1.55)	310 7.23 (2.00)	149 7.39 (1.39)	0.11 (-0.14 to 0.38)	0.38	0.079137
Self-Ordered Search Task	310 7.54 (1.98)	172 7.62 (1.80)	310 7.59 (2.13)	157 7.59 (1.91)	0.09 (-0.28 to 0.45)	0.64	0.04712
Secondary non-cognitive outcomes							

Instrumental Activities of Daily Living Scale	302 0.44 (1.55)	177 0.38 (1.50)	302 0.45 (1.35)	177 0.42 (1.33)	0.02 (-0.18 to - 0.22)	0.86	0.015038
Mild Behaviour Impairment Scale	302 7.31 (15.31)	176 4.98 (13.61)	303 6.92 (11.70)	175 4.16 (7.11)	0.52 (-1.71 to 2.75)	0.65	0.073136
EQ-5D-5L scale	302 0.84 (0.16)	174 0.84 (0.18)	303 0.83 (0.16)	175 0.85 (0.13)	0.00 (-0.03 to 0.03)	0.92	0
EQ-5D-5L VAS	302 76.1 (19.8)	180 77.5 (18.1)	303 76.4 (19.4)	180 77.7 (18.1)	-0.7 (-3.7 to 2.4)	0.69	0.04

Secondary analyses: Impact of supplementation in sub-groups of age, sex and vitamin D deficiency at baseline

Sub-group analyses showed no significant impact on trial outcomes in sub-groups of participants defined by age (five-year age brackets), gender or vitamin D deficiency severity, with the exception of differences between age groups on Paired Associate Learning (P = 0.02) (Table 4).

Table 4 Impact of vitamin D supplementation in sub-groups of age, sex and vitamin D deficiency severity (mild/moderate or severe)

	Age	Sex	Vitamin D deficiency				
Subgroups	50-59 vs. 60-69 vs.	male vs.	Mild/moderate<50nmol/l vs.				
	70-79 vs. 80+ yrs	female	severe <25 nmol				
Primary Outcome							
Trail making B	P=0.69	P=0.79	P=0.97				
Secondary Cognitive Outcomes							
Verbal reasoning	P=0.13	P=0.35	P=0.95				
Paired Associate Learning	P=0.02	P=0.48	P=0.84				
Digit span	P=0.21	P=0.83	P=0.15				

Self-ordered search	P=0.13	P=0.73	Not estimable			
Switching Stroop	P=0.42	P=0.58	Not estimable			
Secondary Non-Cognitive Outcomes						
IADL helplessness	P=0.21	P=0.40	Not estimable			
IADL difficulty	P=0.52	P=0.87	Not estimable			
МВІ	P=0.08	P=0.65	P=0.65			
EQ-5D VAS	P=0.70	P=0.14	P=0.67			
EQ-5D utility score	P=0.37	P=0.88	P=0.92			

#### Per protocol analysis

Usable tablet count data were available in a subgroup of 256 participants. Adjusting for baseline versus follow-up tablet difference showed little or no impact on the treatment-control group effect of vitamin D at 24 months on the primary outcome (mean difference: -6174, 95% CI: -17095 to 4747, P=0.266).

#### Compliance

49 participants were selected to complete a blood test analysis of vitamin D levels for compliance. Of these, 24 returned blood tests at both baseline and 24 months. All participants with blood level data in the intervention group showed improvement in vitamin D deficiency status at 24 months (P<0.001). Of the 256 participants with detailed tablet count data, the median compliance was 98%, and 98% of people had over 80% compliance with the intervention.

### Discussion

This study reports the findings from a remote randomised controlled trial of vitamin D supplementation in older adults with mild to moderate vitamin D deficiency and AACD. The results show that supplementation conferred no benefit to the primary outcome of executive function or to any secondary measures of cognition, function or well-being at the 24-month timepoint. The trial

applied an appropriate double-blinded design and reached sufficient power to answer the research question, so this outcome is reliable and statistically significant.

There is already robust evidence for the benefits of supplementation in people with severe Vitamin D deficiency, but this study clearly shows the absence of benefit in individuals with mild to moderate deficiency, which is more prevalent in the population and less likely to be detected and treated than severe deficiency. The findings suggest that while there is a need to address low vitamin D intake for other health risks, such as osteoarthritis and osteoporosis, there may not be an impact on cognition as a result. There is increasingly clear evidence regarding strategies for promoting cognitive health in ageing, including physical activity, cognitive training, maintaining a healthy weight and managing key medical conditions such as depression, hypertension, diabetes and hearing loss. However, this trial indicates that vitamin D supplementation need not be included in this guidance for the public or clinicians when considering cognitive risk in individuals with moderate deficiency. The important exception is in individuals with severe vitamin D deficiency since this trial did not include sufficient individuals with a deficiency of <25nmol/l, as this was not the primary research question. This study successfully delivered a fully remote randomised placebo-controlled clinical trial in 620 participants. It provides proof of concept for the innovative remote approach to trial delivery. Participants were recruited, treated, assessed and retained using fully remote methodology. Recruitment was achieved at the height of the Covid-19 pandemic in the UK when most clinical trials were halted and in a seven-month timescale that is unprecedented for traditional in-clinic trials. This was particularly successful due to the PROTECT-UK infrastructure, which allows targeted recruitment from the large ageing cohort with full consent for contact. The remote protocol for dispensing and tracking of study tablets was accurate and well-received by participants, and the study achieved good retention of participants across the 24-month period. Participants showed good compliance with the study protocol, as confirmed by the vitamin D blood level results, tablet count data and the completeness of the data. The online safety reporting approach enabled rapid, real-time collation and responsiveness to this low-risk intervention. Furthermore, the online and computerised

assessment platform provided by the PROTECT-UK infrastructure facilitated high-quality data capture and depth of cognitive data without the need for in-person assessments. This study, therefore, provides important proof of concept for the remote trial design approach for low-risk interventions such as dietary supplements, nutraceutical products or repositioned drugs that do not require in-person physiological monitoring.

The study did, however, have some limitations. Recruitment was achieved through the online PROTECT-UK cohort, resulting in a self-selection bias towards females of Caucasian ethnicity with high educational attainment. The online nature of the trial also meant that participants were already fully digitally engaged. These design factors meant that the cohort was not fully representative of the UK population so caution should be taken in translating the findings to a population level, particularly considering the association of vitamin D and differing melatonin levels in different ethnic minority groups. This study was run for 24 months and showed no benefit to cognition so it is possible that a longer duration trial may have shown a more favourable outcome, although this would raise issues regarding the implementability of a long-term supplementation programme for public health.

This study provides robust evidence that Vitamin D supplementation does not result in cognitive benefits in individuals with mild to moderate deficiency. The findings indicate that while supplementation may be of value for other clinical indications and in people with severe deficiency, guidance does not need to include vitamin D supplementation for this patient group. Furthermore, the study provides robust proof of concept for remote clinical trial delivery using recruitment and engagement through the PROTECT-UK cohort platform and integrated computerised cognitive testing. This methodology should be considered for low-risk clinical trials.

## **Acknowledgements**

This work was funded by the Jon Moulton Charitable Foundation. This paper represents independent research part-funded by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. It was also supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South-West Peninsula. JR receives funding from Alzheimer's Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No funding has been provided by a pharmaceutical company or other agency to write this article. Authors have not been precluded from accessing data, and all authors accept responsibility for publication.

https://www.exeter.ac.uk/

### References

 1.
 Alzheimer's
 Research
 UK.
 Dementia
 Statistics
 UK

 https://www.dementiastatistics.org/statistics-about-dementia/prevalence-2/:
 Alzheimer's
 Research

 UK; 2022
 VK
 V

2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75 e2.

3. US Federal Drugs Agency. Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy2018</u>.

4. Ashwell M, Stone EM, Stolte H, Cashman KD, Macdonald H, Lanham-New S, et al. UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr. 2010;104(4):603-11.

5. Scientific Advisory Committee on Nutrition. SACN vitamin D and health report <u>https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report</u>: GOV.UK; 2016 [

6. Crowe FL, Jolly K, MacArthur C, Manaseki-Holland S, Gittoes N, Hewison M, et al. Trends in the incidence of testing for vitamin D deficiency in primary care in the UK: a retrospective analysis of The Health Improvement Network (THIN), 2005-2015. BMJ Open. 2019;9(6):e028355.

7. Anjum I, Jaffery SS, Fayyaz M, Samoo Z, Anjum S. The Role of Vitamin D in Brain Health: A Mini Literature Review. Cureus. 2018;10(7):e2960.

8. Miller BJ, Whisner CM, Johnston CS. Vitamin D Supplementation Appears to Increase Plasma Aβ40 in Vitamin D Insufficient Older Adults: A Pilot Randomized Controlled Trial. J Alzheimers Dis. 2016;52(3):843-7.

9. Durk MR, Han K, Chow EC, Ahrens R, Henderson JT, Fraser PE, et al.  $1\alpha$ ,25-Dihydroxyvitamin D3 reduces cerebral amyloid- $\beta$  accumulation and improves cognition in mouse models of Alzheimer's disease. J Neurosci. 2014;34(21):7091-101.

10. Llewellyn DJ, Langa KM, Lang IA. Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol. 2009;22(3):188-95.

11. Ghahremani M, Smith EE, Chen HY, Creese B, Goodarzi Z, Ismail Z. Vitamin D supplementation and incident dementia: Effects of sex,. Alzheimers Dement (Amst). 2023;15(1):e12404.

12. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, et al. 1alpha,25dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17(3):703-17.

13. Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170(13):1135-41.

14. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920-8.

15. Navale SS, Mulugeta A, Zhou A, Llewellyn DJ, Hyppönen E. Vitamin D and brain health: an observational and Mendelian randomization study. Am J Clin Nutr. 2022;116(2):531-40.

16. Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79(13):1397-405.

17. PROTECT Study Website. Contract No.: 15th December.

18. Huntley J, Corbett A, Wesnes K, Brooker H, Stenton R, Hampshire A, et al. Online assessment of risk factors for dementia and cognitive function in healthy adults. Int J Geriatr Psychiatry. 2018;33(2):e286-e93.

19. Huntley J, Corbett A, Wesnes K, Brooker H, Stenton R, Hampshire A, et al. Online assessment of risk factors for dementia and cognitive function in healthy adults. International journal of geriatric psychiatry. 2018;33(2):e286-e93.

20. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: the English longitudinal study of ageing. Int J Epidemiol. 2013;42(6):1640-8.

21. Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000;22(4):518-28.

22. Owen AM, Hampshire A, Grahn JA, Stenton R, Dajani S, Burns AS, et al. Putting brain training to the test. Nature. 2010;465(7299):775-8.

23. Corbett A, Owen A, Hampshire A, Grahn J, Stenton R, Dajani S, et al. The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. Journal of the American Medical Directors Association. 2015;16(11):990-7.

24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-86.

25. Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195-202.

26. EuroQolGroup. EuroQol—a new facility for the measurement of health related quality of life. Health Policy (New York). 1990;16:199-208.

27. Corbett A, Owen A, Hampshire A, Grahn J, Stenton R, Dajani S, et al. The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. Journal of the American Medical Directors Association. 2015;16(11):990-7.



